LEXG-Lexicon Genetics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LEXG-Lexicon Genetics

LXRX 1.390

+3.7%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: nigel bates	6/20/2005 11:15:20 AM
	Read Replies (1) of 254

Lexicon Genetics Inc. Initiates Project With Odyssey Thera Monday June 20, 11:00 am ET SAN RAMON, Calif., June 20 /PRNewswire/ -- Odyssey Thera, Inc. announced today an agreement with Lexicon Genetics, Inc. to characterize the pathway activity of certain Lexicon compounds in human cells. The announcement marks the fifth such agreement for Odyssey Thera. Odyssey Thera's protein-fragment complementation assay (PCA) strategy allows for the on-pathway and off-pathway activities of compounds to be visualized and quantified directly in living human cells. Each of hundreds of assays reports on the sub-cellular activity of a compound at a particular node or branch of a biochemical pathway. By testing a compound against a broad panel of distinct assays, both intended and unintended activities can be identified and can be traced to a particular pathway and mechanism of action. Odyssey Thera's database of known drugs and toxic compounds further informs the process, allowing a comparison of the activity of novel compounds with the activities of marketed and withdrawn agents and toxicants. About Odyssey Thera Odyssey Thera, Inc. is a privately held biotechnology company that is pioneering a pathway-based approach to drug discovery. The use of human cells instead of isolated proteins aids in the identification of drug leads with desirable profiles, and enables early attrition of compounds with unintended effects in human cells. The company is applying its strategy both for the benefit of its pharmaceutical partners, and to identify small molecules that block key cancer pathways in man. For more information, please visit the company website at www.odysseythera.com. ------------------------------------------------------------------------

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next